このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kintor Pharmaceutical 過去の業績

過去基準チェック /06

Kintor Pharmaceuticalの収益は年間平均-27.9%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間11.7% 21.2%割合で増加しています。

主要情報

-27.9%

収益成長率

-19.1%

EPS成長率

Biotechs 業界の成長	11.0%
収益成長率	21.2%
株主資本利益率	-231.6%
ネット・マージン	n/a
前回の決算情報	31 Dec 2023

Recent updates

収支内訳

Kintor Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:9939 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 23	0	-1,061	96	939
30 Sep 23	0	-854	116	735
30 Jun 23	0	-648	136	532
31 Mar 23	0	-801	144	680
31 Dec 22	0	-954	153	828
30 Sep 22	17	-995	145	887
30 Jun 22	34	-1,035	138	947
31 Mar 22	34	-938	128	857
31 Dec 21	34	-842	118	768
30 Sep 21	17	-740	116	615
30 Jun 21	0	-639	114	463
31 Mar 21	0	-573	100	396
31 Dec 20	0	-508	86	329
30 Sep 20	0	-419	63	301
30 Jun 20	0	-330	39	273
31 Mar 20	0	-281	30	243
31 Dec 19	0	-233	21	214
31 Dec 18	1	-108	24	93
31 Dec 17	0	-46	50	0
30 Sep 17	0	-41	44	0
30 Jun 17	0	-35	39	0
31 Mar 17	1	-45	49	0
31 Dec 16	1	-54	60	0
31 Dec 15	0	-11	14	0

質の高い収益: 9939は現在利益が出ていません。

利益率の向上: 9939は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 9939は利益が出ておらず、過去 5 年間で損失は年間27.9%の割合で増加しています。

成長の加速: 9939の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 9939は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 22.1% ) と比較することは困難です。

株主資本利益率

高いROE: 9939は現在利益が出ていないため、自己資本利益率 ( -231.56% ) はマイナスです。

Kintor Pharmaceutical 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Recent updates

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New major risk - Share price stability

Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA

Founder recently bought HK$774k worth of stock

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

New minor risk - Share price stability

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

New major risk - Financial position

Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Insider recently sold HK$2.6m worth of stock

Insider recently sold HK$42m worth of stock

New major risk - Revenue and earnings growth

Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023

Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China

Insider recently sold HK$12m worth of stock

Forecast to breakeven in 2023

Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million.

Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China

Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc

Consensus revenue estimates fall by 98%

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us

Key Executive recently sold HK$5.7m worth of stock

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022

Insider recently sold HK$60m worth of stock

Kintor Pharmaceutical Limited Announces Board Changes

Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

Forecast breakeven date pushed back to 2023

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19

Forecast breakeven date pushed back to 2023

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients

Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited Announces Executive Changes

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne

Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Deputy GM & Joint Company Secretary Jie Chen has left the company

Non-Executive Director Wei Zhang has left the company

Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826

Kintor Pharmaceutical Limited Announces the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized Covid-19 Patients

Non-Executive Director recently bought HK$4.3m worth of stock

Kintor Pharmaceutical Limited Announces Primary Endpoint of Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia

Is Kintor Pharmaceutical (HKG:9939) Using Debt Sensibly?

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

Kintor Pharmaceutical Limited Announces Investigational New Drug (IND) Clearance by the US FDA for GT20029 for Androgenetic Alopecia and Acne Vulgaris

Kintor Pharmaceutical Announces FDA Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US

Consensus forecasts updated

Kintor Pharmaceutical Limited Receives Approval from Razilian Health Regulatory Agency in the Phase III Clinical Trial of Proxalutamide for Treatment of Male Patients with Mild to Moderate COVID-19 Illness

FDA Approves the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalised COVID-19 Patients

Non-Executive Director has left the company

Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S

Kintor Pharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

過去基準チェック /06